Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
We recently published a list of 11 Stocks That Will Go to the Moon According to Reddit. In this article, we are going to take ...
Key Takeaways Moderna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion.The company expects ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management ...
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The ...
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...
Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...
Moderna share price took a blow as CEO Stéphane Bancel outlined a diminished guidance for 2025. Credit: Boston Globe/ Getty Images Moderna lost more than 20% of its value on the stock market as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback